Evidence map›Paper›PMID 41381239›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody.

Sara Lopes van den Broek, Klas Bratteby, Ximena Aguilar, Thuy A Tran, Stina Syvänen, Dag Sehlin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara Lopes van den BroekDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Klas BrattebyDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; and.
Ximena AguilarDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Thuy A TranDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; and.
Stina SyvänenDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Dag SehlinDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; dag.sehlin@uu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bispecific antibodies exploiting receptor-mediated transcytosis offer a promising strategy to overcome limited blood-brain barrier permeability in Alzheimer disease immunotherapy and imaging. Lecanemab-Fab8D3 (Lec-Fab8D3), a bispecific amyloid-β (Aβ) antibody with enhanced brain delivery, may complement lecanemab immunotherapy as an immuno-PET imaging agent. Here, we systematically assess how the choice of radionuclide affects PET detection of Lec-Fab8D3 within the brain to evaluate its potential as a companion diagnostic.

Indexed as

Amyloid beta-PeptidesAntibodies, BispecificBrainPositron-Emission TomographyRadioisotopesAnimalsCopper RadioisotopesIodine RadioisotopesMiceTissue DistributionZirconiumAmyloid beta-PeptidesAntibodies, BispecificCopper-64Copper RadioisotopesIodine-124Iodine RadioisotopesRadioisotopesZirconiumZirconium-89Alzheimer diseaseblood–brain barrierimmuno-PETPETradionuclide

Identifiers

PMID41381239
PMCPMC12955504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.